<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40259">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01992523</url>
  </required_header>
  <id_info>
    <org_study_id>MOJITO Study</org_study_id>
    <nct_id>NCT01992523</nct_id>
  </id_info>
  <brief_title>Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )</brief_title>
  <official_title>Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Antoniucci</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ARCARD ONLUS Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Careggi Hospital</source>
  <oversight_info>
    <authority>Italy: The Italian Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the Mashed Or Just Integral pill of TicagrelOr (MOJITO) study is to evaluate the
      superiority of Ticagrelor 180 mg LD mashed pill versus Ticagrelor 180 mg LD integral pill
      both orally administrated in decreasing residual platelet reactivity 1 hour after the
      administration among 70 patients with STEMI (ST segment elevation myocardial infarction)
      undergoing PPCI with bivalirudin monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>residual platelet reactivity</measure>
    <time_frame>1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>residual platelet reactivity by Platelet Reactivity Units (PRU) VerifyNow 1 hour after ticagrelor LD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>high residual platelet reactivity</measure>
    <time_frame>1, 2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percent of patients with a high residual platelet reactivity (PRU &gt; 208) 1 hour and 2 hours after ticagrelor LD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Major, minor, minimal bleeding (TIMI criteria) events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnoea and/or symptomatic bradycardia</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Occurrence of dyspnoea and/or symptomatic bradycardia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Adverse Reaction to Antiplatelet Agent</condition>
  <arm_group>
    <arm_group_label>Ticagrelor mashed pills</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor loading dose (LD) 180 mg as mashed pills</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor integral pills</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ticagrelor loading dose (LD) 180 mg as integral pills</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor mashed pills</intervention_name>
    <description>The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor). Mashed pills administration will be prepared placing 2 ticagrelor pills in a mortar and mashing for 60 seconds using a pestle. The total contents of the mortar will be transferred to the dosing cup, 50 mL of purify water will be added, and the suspension mixed up before drinking. Afterwards, 100 mL of purify water will be administered to the patient.</description>
    <arm_group_label>Ticagrelor mashed pills</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor integral pills</intervention_name>
    <description>The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor).</description>
    <arm_group_label>Ticagrelor integral pills</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting within 12 hours from the onset of symptoms with STEMI

          -  Informed, written consent

        Exclusion Criteria:

          -  Age &lt; 18 years or Age &gt; 75 years

          -  Active bleeding; bleeding diathesis; coagulopathy

          -  Increased risk of bradycardiac events

          -  History of gastrointestinal or genitourinary bleeding &lt;2 months

          -  Major surgery in the last 6 weeks

          -  History of intracranial bleeding or structural abnormalities

          -  Suspected aortic dissection

          -  Any other condition that may put the patient at risk or influence study results or
             investigator's opinion (severe hemodynamic instability, known malignancies or other
             comorbid conditions with life expectancy &lt;1 year)

          -  Administration in the week before the index event of clopidogrel, ticlopidine,
             prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or
             fondaparinux .

          -  Concomitant oral or IV therapy with strong CYP3A inhibitors or strong CYP3A inducers,
             CYP3A with narrow therapeutic windows

          -  Known relevant hematological deviations: Hb &lt;10 g/dl, Thrombi. &lt;100x10^9/l

          -  Use of coumadin derivatives within the last 7 days

          -  Chronic therapy with ticagrelor, prasugrel, clopidogrel or ticlopidine

          -  Known severe liver disease, severe renal failure

          -  Known allergy to the study medications

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guido Parodi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Careggi Hospital, Division of Invasive Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Antoniucci, MD</last_name>
    <role>Study Director</role>
    <affiliation>Careggi Hospital, Division of Invasive Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guido Parodi, MD</last_name>
    <phone>+390557947732</phone>
    <email>parodiguido@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiology, Patras University Hospital</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitrios Alexopoulos, MD</last_name>
      <email>dalex@med.upatras.gr</email>
    </contact>
    <investigator>
      <last_name>Dimitrios Alexopoulos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Careggi Hospital</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guido Parodi, MD</last_name>
      <phone>+390557947732</phone>
      <email>parodiguido@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Guido Parodi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 13, 2014</lastchanged_date>
  <firstreceived_date>November 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Careggi Hospital</investigator_affiliation>
    <investigator_full_name>David Antoniucci</investigator_full_name>
    <investigator_title>Director, Division of Invasive Cardiology</investigator_title>
  </responsible_party>
  <keyword>Ticagrelor</keyword>
  <keyword>antiplatelet</keyword>
  <keyword>Acute Coronary Syndrome</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
